Domů › Nemalobuněčný plicní karcinom › Virginia › Richmond
Klinické studie Nemalobuněčný plicní karcinom v Richmond, VA
25 studií pro Nemalobuněčný plicní karcinom hledá účastníky v lokalitách v Richmond a okolí (do cca 30 mil). Otevřete studii a zjistěte, kdo se může zapojit a jak kontaktovat tým studie.
Oficiální text studie (anglicky)
Hledáte účastníky pro studii? Zvýrazněte ji nahoře na této stránce – $99 na 30 dní →
Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])
Probíhá náborFáze 3
- Virginia Cancer Institute, Richmond
- VCU Massey Cancer Center at Stony Point, Richmond
- VCU Massey Comprehensive Cancer Center, Richmond
A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009)
Probíhá náborFáze 3
- VCU Health Adult Outpatient Pavillion ( Site 0193), Richmond
Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT Trial
Probíhá náborFáze 3
- Virginia Cancer Institute, Richmond
A Study to Evaluate the Efficacy of Pumitamig Versus Pembrolizumab in Participants With Previously Untreated Advanced Non-Small Cell Lung Cancer and PD-L1 ≥ 50%. (ROSETTA Lung-202)
Probíhá náborFáze 3
- Local Institution - 0337, Richmond
A Study to Learn About the Study Medicine Called PF-08046054/SGN-PDL1V Versus Docetaxel in Adult Participants With Previously-Treated Programmed Cell Death Ligand 1 (PD-L1) Positive Non-Small-Cell Lung Cancer (NSCLC)
Probíhá náborFáze 3
- VCU Medical Center Gateway Building, Richmond
- Virginia Commonwealth University, Richmond
- VCU Health Short Pump Pavilion, Richmond
- a dalších 4
Symbiotic-Lung-20: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Different Anticancer Agents in Advanced Cancers
Probíhá náborFáze 1/2
- VCU Medical Center Gateway Building, Richmond
- Virginia Commonwealth University, Richmond
- VCU Health Stony Point, Richmond
- a dalších 2
Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer
Probíhá náborFáze 3
- VCU Health Adult Outpatient Pavillion, Richmond
Pan-tumor MRD Study
Probíhá náborObservační studie
- Virginia Cancer Institute, Richmond
Phase III, Open-label, Study of First-line Dato-DXd in Combination With Rilvegostomig for Advanced Non-squamous NSCLC With High PD-L1 Expression (TC ≥ 50%) and Without Actionable Genomic Alterations
Probíhá náborFáze 3
- Research Site, Richmond
- Research Site, Midlothian · Vzdálenost 11 mi
Safety, Efficacy, and Pharmacokinetics of BNT327 in Combination With Chemotherapy and Other Investigational Agents for Lung Cancer
Probíhá náborFáze 2/3
- VCU Massey Cancer Center, Richmond
Study of Izalontamab Brengitecan (BMS-986507) Versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer After Failure of EGFR TKI Therapy (IZABRIGHT-Lung01)
Probíhá náborFáze 2/3
- Virginia Commonwealth University (Vcu), Richmond
Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients With High PD-L1
Probíhá náborFáze 3
- Clinical Study Site, Richmond
- Clinical Study Site, Richmond
Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7
Probíhá náborFáze 2/3
- Virginia Cancer Institute - West End, Richmond
A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer
Probíhá náborFáze 3
- VCU Health Adult Outpatient Pavillion, Richmond
Phase III, Open-label Study of First-line Osimertinib With or Without Datopotamab Deruxtecan for EGFRm Locally Advanced or Metastatic Non-small Cell Lung Cancer
Probíhá náborFáze 3
- Research Site, Midlothian · Vzdálenost 11 mi
Clinical Trial of N-803 Plus Tislelizumab or Prior Failed Immune Checkpoint Inhibitor and Docetaxel Versus Docetaxel Monotherapy in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Acquired Resistance to Immune Checkpoint In
Probíhá náborFáze 3
- Virginia Commonwealth University, Richmond
Radiotherapy to Block Oligoprogression In Metastatic Non-Small-Cell Lung Cancer
Probíhá náborFáze 3
- VCU Massey Cancer Center at Stony Point, Richmond
- VCU Massey Comprehensive Cancer Center, Richmond
Autologous LN-145 in Patients With Metastatic Non-Small-Cell Lung Cancer
Probíhá náborFáze 2
- VCU Medical Center (Virginia Commonwealth University), Richmond
Reduced CT + Anti-PD-1 as First Line Tx in Vulnerable Older Adults w/Adv <50% PD-L1 Non-Small Cell Lung Cancer (NSCLC)
Probíhá náborFáze 2
- Virginia Commonwealth University, Richmond
Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has Increased Copies of the MET Gene (An Expanded Lung-MAP Treatment Trial)
Probíhá náborFáze 2
- Virginia Cancer Institute, Richmond
- VCU Massey Cancer Center at Stony Point, Richmond
- VCU Massey Comprehensive Cancer Center, Richmond
Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With Advanced Non-Small Cell Lung Cancer Who Had Previous Treatment With Platinum Chemotherapy and Immunotherapy (An Expanded Lung-MAP Treatment Trial)
Probíhá náborFáze 2/3
- Virginia Cancer Institute, Richmond
- VCU Massey Cancer Center at Stony Point, Richmond
- VCU Massey Comprehensive Cancer Center, Richmond
Adjuvant Pembrolizumab vs Observation Following Curative Resection for Stage I Non-small Cell Lung Cancer (NSCLC) With Primary Tumors Between 1-4 cm
Probíhá náborFáze 2
- Virginia Commonwealth University, Richmond
Adagrasib + SRS for Patients With Metastatic KRAS G12C-mutated NSCLC With Untreated Brain Metastases
Probíhá náborFáze 2
- Virginia Commonwealth University, Richmond
Assessing Benefits and Harms of Cannabis/Cannabinoid Use Among Cancer Patients Treated in Community Oncology Clinics
Probíhá náborObservační studie
- VCU Massey Cancer Center at Stony Point, Richmond
- Virginia Commonwealth University/Massey Cancer Center, Richmond
Repositioning Immunotherapy in VetArans With Lung Cancer
Probíhá náborFáze 2
- Richmond VA Medical Center, Richmond, VA, Richmond
Studie Nemalobuněčný plicní karcinom v jiných městech
- Houston, TX145 studií
- New York City, NY121 studií
- Arlington, VA104 studií
- Nashville, TN97 studií
- Boston, MA90 studií
- Los Angeles, CA87 studií
- St. Louis, MO73 studií
- Chicago, IL61 studií
- Baltimore, MD60 studií
- San Antonio, TX59 studií
- Columbus, OH57 studií
- Washington, DC55 studií
Další studie v Richmond
- Rakovina prsu26 studií
- Rakovina prostaty19 studií
- Srdeční selhání16 studií
- Rakovina plic14 studií
- Kardiovaskulární onemocnění13 studií
- Kolorektální karcinom13 studií
- Steatotické onemocnění jater12 studií
- Akutní myeloidní leukemie12 studií
- Metastatický karcinom12 studií
- Squamózní buněčný karcinom hlavy a krku12 studií
- Melanom11 studií
- Obesity11 studií
Zdroj: ClinicalTrials.gov, data načtena 6. 10. 2026. Každá studie má vlastní kritéria způsobilosti; o účasti rozhoduje tým studie.